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Abstract The optimal treatment of sinonasal undiVerenti-
ated carcinoma (SNUC) remains unclear. We report our
results on the outcome and toxicity of patients with SNUC
treated by a combined modality and attempt to deWne the
optimal treatment strategies by reviewing the literature.
Between 1996 and 2010, 21 consecutive patients with
SNUC were treated by any combination of surgery, chemo-
therapy and radiotherapy. End points were local control
(LC), regional control (RC), disease-free (DFS), cause-spe-
ciWc (CSS) overall survival (OS), and late toxicity. Organ
preservation was deWned as visual preservation without orbi-
tal exenteration. After median follow-up of 54 months, the
5-year actuarial rates of LC, RC, DFS, CSS, and OS were
80, 90, 64, 74, and 74 % respectively. On multivariate analy-
sis, T-stage and multimodality treatment approach correlated
signiWcantly with LC. Elective nodal irradiation was given
to 42 % of high-risk node-negative patients. None of them
developed regional failure. The overall 5-year incidence of
grade ¸2 late toxicity was 30 %. Treatment-related blind-
ness was signiWcantly decreased in patients treated with
intensity-modulated radiotherapy (IMRT), compared to 2D
and 3D-conformal radiotherapy (3DCRT), with organ pres-
ervation rates of 86 and 14 % respectively (p = 0.006). We
concluded that combined-modality treatment with three, or
at least two, modalities resulted in good LC, but with high
overall rate of late toxicity. However, the incidence of late
toxicity and permanent visual impairment were decreased
over time by the introduction of IMRT. Because of the
improvement in therapeutic ratio achieved by using IMRT,
this highly conformal radiation technique should be the stan-
dard of care in patients with SNUC.
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Introduction
Sinonasal undiVerentiated carcinoma (SNUC) is a rare type
of malignancy which was Wrst described by Frierson et al.
[1]. SNUCs are usually presented at locally advanced stage
involving the nasal cavity and paranasal sinuses with a pro-
pensity to extend into the (peri) orbital tissues and the cen-
tral nervous system. In most series, 10–30 % of patients
have a node-positive disease at diagnosis [2–8]. The origi-
nal reports on SNUC by Frierson et al. [1] painted a grim
picture because of the aggressive nature of the disease and
the limited knowledge about treatment. Early reports on
radiation or surgical resection alone have generally yielded
poor results [1, 9]. By multimodality therapy many patients
achieve complete remission and prolonged survival, with a
signiWcant number potentially cured. Although diVerent
combination of surgery, chemotherapy and radiotherapy are
nowadays used [2–8], there is still no consensus about
which modalities to use and the best sequence.
In the current study we report on a long-term single-
institutional experience of the treatment of SNUC by com-
bined modality. We also performed an exact logistic regres-
sion analysis to identify the parameters predictive of local
failure and reviewed the literature.
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Between September 1996 and September 2010, 21 consec-
utive patients with SNUC were treated with curative intent
at our institution by any combination of surgery, radiother-
apy, and chemotherapy (Table 1). Patients with recurrent or
metastatic disease at presentation were excluded from this
analysis.
Pre-treatment evaluation consisted of complete history
and physical examination. All patients had chest X-ray,
ultrasonography with Wne-needle aspiration, and head and
neck MRI or CT scan. All patients were presented in our
weekly multidisciplinary head and neck conference. Based
on the joint recommendations of that meeting, patients
were selected for treatment with surgery followed by
(chemo) radiotherapy, induction chemotherapy followed by
surgery and radiotherapy, or deWnitive (chemo) radiother-
apy. The goal of surgery is complete resection of the tumor
with negative margins, with as low morbidity as possible.
The type and extension of the surgery is dictated by the
extent of the disease, and cosmetic and functional consider-
ations. The surgical techniques ranged from (sub) total
maxillectomy and/or ethmoidectomy to craniofacial resec-
tion. Endoscopes were used when reduction of morbidity or
improved (angled) visualization could be achieved. Orbital
exenteration is not an elective procedure but mandatory in
patients with tumor invasion beyond the periorbital tissue.
Criteria for unresectability were extensive intracranial or
intradural spread, invasion of the optic pathway, invasion
of cavernous sinus, and encasement of the carotid artery.
These patients are oVered either induction chemotherapy
followed by surgery and postoperative radiotherapy
(PORT) or deWnitive (chemo) radiation.
Radiotherapy
Patients were immobilized in a supine treatment position in
a custom-made mask. A computer tomography simulation,
with a 2.5-mm slice thickness, was performed. During the
time span of the study, three diVerent radiation techniques
were used (Table 1). Two patients received radiotherapy
using a two-dimensional three-Weld technique (one anterior
and two laterals wedged). The lens was shielded at the ante-
rior portal. After 54 Gy, the optic pathway was excluded.
However, when the tumor was located very close to or
invaded the optic apparatus, a dose of >54 Gy to the optic
pathway was given, after discussion with patient. In Wve
patients, 3DCRT was used. From 2002 onward, a highly
conformal radiation technique, intensity-modulated radio-
therapy (IMRT), was introduced to treat all head and neck
cancer patients at our institution. Since that time, 14 patients
(66 %) were treated by means of IMRT. The clinical target
volume (CTV) to the planning target volume (PTV) margin
was 5 mm for 3DCRT and IMRT. Radiotherapy was given
at a total dose of 50–70 Gy in the 2-Gy fraction daily in case
of 3DCRT and IMRT. According to the local protocol for
the treatment of paranasal sinus cancers, elective nodal irra-
diation (ENI) was advocated in high-risk node-negative
Table 1 Patient, tumor, and treatment characteristics (n = 21)
PORT post-operative radiotherapy; POCRT post-operative chemora-
diotherapy; CRT chemoradiotherapy; RT radiotherapy; 3DCRT three-
dimensional conformal RT; IMRT intensity-modulated RT
a Patients were staged according to the AJCC staging system for nasal
cavity and ethmoid sinus (Greene F, Page D, Fleming I, editors. Amer-
ican Joint Committee on Cancer, Nasal Cavity and Paranasal Sinuses
(AJCC Cancer Staging Manual), New York, Springer-Verlag; 2002,
pp 61–62
No. of patients (%)
Gender
Male 11 (52 %)
Female 10 (48 %)
Age (years)
Range 26–78
Median 52
Follow-up (months)
Range 4–163
Median 54
Tumor stagea
T3 6 (29 %)
T4a 6 (29 %)
T4b 9 (42 %)
Nodal stagea
N0 19 (90 %)
N+ 2 (10 %)
Site
Ethmoid sinus 16 (76 %)
Maxillary sinus 5 (24 %)
Dural or orbital invasion
No 14 (67 %)
Dural invasion 3 (13 %)
Orbital invasion 4 (20 %)
Type of treatment
Primary CRT 7 (33 %)
Induction CT, surgery, and PORT 7 (33 %)
Surgery and PORT 5 (24 %)
Surgery and POCRT 2 (10 %)
Radiation dose (Gy)
Range 50–70
Median 62.5
Technique radiotherapy
2D conventional RT 2 (10 %)
3DCRT 5 (24 %)
IMRT 14 (66 %)123
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poral fossa, pterygoid, or cribriform plates.
Chemotherapy
Sixteen patients (76 %) received chemotherapy. Concurrent
chemoradiotherapy (n = 9) (seven deWnitive and two post-
operative) was given using two cycles of cisplatin (100 mg/
m2, day 1 and 21) and induction chemotherapy (n = 7)
using four cycles of cisplatin (80 mg/m2 day 1) and etopo-
side (100 mg/m2 day 1, 2 and 3).
End points
End points of the study were rates of local control (LC),
regional control (RC), and disease-free (DFS), cause-spe-
ciWc (CSS) and overall survival (OS). The late toxicity
scores were retrospectively collected from chart review
using common terminology criteria for adverse events v3.0
(CTCAE). Organ preservation was deWned as visual preser-
vation without orbital exenteration.
Follow-up
After completion of treatment, patients were followed up 2-
monthly for the Wrst year, 3-monthly for the second and
third year, and 6-monthly thereafter. At each visit, history
and clinical examinations were performed.
Statistical analysis
Survival rates were calculated from the completion of treat-
ment using Kaplan–Meier technique. Possible predictive
clinicopathological factors for local failure were tested
using exact logistic regression model. All signiWcant tests
were two sided and p values <0.05 were considered to be
statistically signiWcant.
Results
The patient’s characteristics are shown in Table 1. The
tumor was occupying at least two paranasal sinuses. How-
ever, the tumor epicenter was in the ethmoid sinus in 76 %,
and the maxillary sinus in 24 % of patients.
Outcomes
After a median follow-up of 54 months (range 4–163), the
5-year actuarial rates of LC, RC, DFS, CSS, and OS were
80, 90, 64, 74, and 74 % respectively (Fig. 1).
Twelve events were reported: eight in-Weld local (LF),
two regional (RF), and two distant failures, resulting in
absolute LC, RC, distant metastasis-free survival (DMFS),
and DFS rates of 62, 91, 91, and 48 %, respectively. The
median time from treatment completion to any progression
was 16 months (range 4–144).
Two of LFs were successfully salvaged with surgery and
postoperative stereotactic radiotherapy. One of them under-
went orbital exenteration as a part of the salvage surgery. In
other patients with LF (n = 6), local treatment was not pos-
sible and they died eventually because of local progression.
The median time from the treatment failure to death was
4 months (range 1–13).
Two patients had node-positive disease; one patient
underwent neck dissection (ND) at the same session of the
craniofacial resection and the second patient received
70 Gy radiotherapy to the primary tumor and the involved
neck. Of the 19 node-negative patients, 8 patients (42 %)
received elective nodal irradiation (ENI) (46–50 Gy) to the
ipsilateral neck (level I–III). Of the entire group, only two
patients developed RF and none of them received ENI; both
were successfully salvaged with ND and PORT (66 Gy).
Of the whole group, six patients (29 %) died; in all of
them, the cause of death was cancer related: in Wve patients
because of local progression and in one patient because of
both LF and DM.
On univariate analysis, high T-stage, the use of two-
instead of three-modality treatment approach, the presence
of dural or orbital invasion, and the omission of surgical
treatment were signiWcantly correlated with poor LC. How-
ever, on multivariate analysis only the Wrst two parameters
were still independently correlated with poor LC (Table 2).
Fig. 1 Kaplan–Meier curve of local control (LC), regional control
(RC), cause-speciWc (CSS), disease-free (DFS) and overall survival
(OS)
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The overall 5-year cumulative incidence of grade ¸2 late
toxicity was 30 %. Ten serious complications were reported
in six patients, 50 % of these complications were ocular
including unilateral blindness (n = 2), lacrimal duct steno-
sis (n = 2), and ectropion (n = 1). Non-ocular complications
were dysphagia (n = 2), xerostomia (n = 1), deafness
(n = 1), and maxillary osteoradionecrosis (n = 1). The inci-
dence of late toxicity was reduced over time with the intro-
duction of highly conformal radiotherapy techniques as
IMRT. The incidence of serious complications in patients
treated with IMRT versus 2D and 3DCRT were 14 and
57 %, respectively. None of the 14 patients treated with
IMRT developed treatment-related blindness, while two of
seven patients (29 %) treated by means of 2D or 3DCRT
developed unilateral blindness.
Of the entire group, six patients had permanent visual
problems because of tumor and/or treatment-related fac-
tors: three patients underwent orbital exenteration during
the primary or salvage surgery because of LF, one patient
was inoperable and the eye globe was not functional any
more, and two patients developed treatment-related
blindness resulting in an ultimate organ preservation of
71 %. Organ preservation was signiWcantly improved
over time in patients treated by IMRT, compared to 2D
and 3DCRT (86 and 14 %, respectively, p = 0.006), since
no patient treated with IMRT developed treatment-
related blindness, compared to two patients treated with
2D/3DCRT.
Discussion
Since SNUC was Wrst introduced in 1986, only seven stud-
ies reporting on the outcome of ¸10 patients have been
published from diVerent institutions in the USA and Aus-
tralia. Gallo et al. [10] published in 1993 an immunohisto-
chemical study on 13 patients with SNUC and reported
brieXy on the outcome of these patients treated at the Uni-
versity of Florence between 1970 and 1993, mainly with
radiotherapy. Only one patient was treated surgically and
four with non-platinum-based chemotherapy. The present
study is one of the largest and is the Wrst European study to
date reporting on outcome and toxicity of patients treated at
the Erasmus MC-Daniel den Hoed Cancer Center in the era
of modern surgical and radiation techniques and platinum-
based chemotherapy regimens.
Table 3 illustrates patients’ demographics and outcomes
of eight studies where patients with SNUC were treated
with combined-modality treatment. Our review included
only studies where at least ten patients were treated because
smaller series cannot provide the means to draw solid con-
clusions. Comparison between these studies is complicated
by major diVerences with respect to patients’ demograph-
ics, the used staging system, end points and therapeutic
strategies. Patients’ characteristics and outcomes of the cur-
rent study have more similarities with the reported data
from the University of Florida [6] and the M.D. Anderson
Cancer Center [5]. Small diVerences were observed, for
instance in the length of the follow-up time, type of chemo-
therapy used, and the percentages of patients having T4
tumor, who received chemotherapy and were irradiated by
means of IMRT. As shown in Table 3, the outcomes in the
current study compares favorably with those reported in the
other Wve studies. Possible explanations are [1] that higher
radiation dose and highly conformal radiation techniques
were mostly applied in our study. Dose–response relation-
ship might exist in case of SNUC [11]. In the present study,
patients who received >60 Gy showed better LC rates,
compared to a dose of ·60 Gy (75 vs. 44 %), albeit statisti-
cally not signiWcant. The same is true for patients treated
with IMRT, compared to 2D or 3DCRT (77 vs. 38 %). In
patients treated with 2D or 3DCRT, underdosage of the tar-
get volume should often be tolerated to prevent late toxic-
ity. Dirix et al. [12] showed that IMRT, compared to
3DCRT, improved DFS (p = 0.02) and LC (p = 0.06) and
decreased acute and late toxicity [2]. Relatively more T4
tumors and (when reported) more tumors with orbital and/
or intracranial invasion were treated in other studies [3]. In
our study, more patients received induction chemotherapy
with down-staging and subsequently resection and PORT.
In most of the reviewed studies, the beneWt of implementa-
tion of aggressive surgery as part of the treatment modality
was clearly demonstrated [2–8]. In our study, the patients
Table 2 Exact logistic regression analysis: correlation between diVer-
ent parameters and local failure
SigniWcant p values are indicated in bold
NS nonsigniWcant p value; LF local failure; UVA univariate analysis;
MVA multivariate analysis; OR odds ratio; RT radiotherapy; 2D two-
dimensional; 3DCRT three-dimensional conformal radiotherapy;
IMRT intensity-modulated radiotherapy
UVA 
(p value)
MVA 
(OR and p value)
T-stage (T4 vs. T3) 0.02 36 (0.002)
N-stage (N+ vs. N0) 0.99
Tumor site (ethmoid vs. maxillary) 0.68
Dural or intracranial extension 
(yes vs. no)
0.005 NS
Surgery (no vs. yes) 0.02 NS
Treatment modalities (two vs. three) 0.004 55 (0.0003)
RT technique (2D and 3DCRT 
vs. IMRT)
0.17
RT dose (·60 Gy vs. >60 Gy) 0.76123
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LC than those in whom it was omitted (85 vs. 25 %,
p = 0.005). Adding induction chemotherapy to achieve
down-staging before surgery should be considered, when
resectability upfront is questionable. Carful selection of
patients who are more likely to beneWt from an attempt at
such an organ preservation approach is of paramount
importance. The beneWt of induction chemotherapy to
reduce the incidence of DM was suggested by Rischin et al.
[8], since none of the seven patients with SNUC treated
with induction followed by concurrent chemotherapy
developed DM (follow-up 8-62 months), whereas both
patients treated with surgery and PORT developed DM at 8
and 20 months, respectively.
In the reviewed literature, the incidence of node-positive
disease at presentation varied from 10 to 30 % (mean 13 %).
In our study, 42 % of high-risk node-negative patients
received ENI. None of them developed RF. Two RFs were
reported in patients who did not receive ENI, resulting in
regional control rates of 100 and 82 % for patients who did
or did not receive ENI, respectively. Our results are compa-
rable with those reported by the University of Florida (100
and 66 %) [6] and the University of California (94 and
75 %) [2]. However, Rischin et al. [8] reported a 50 % nodal
recurrence rate. In that study, ENI was, to our knowledge,
not applied. The question whether ENI should be given to all
patients with SNUC is diYcult to answer because in most of
these studies ENI is recommended on a case-by-case basis.
However, the results of the small studies (where ENI was
applied) are encouraging with respect to regional control.
Therefore, we would advocate ENI in patients with locally
advanced SNUC. According to our local treatment protocol,
ENI was advocated in T4 high-risk node-negative patients
with involvement of the skin of the cheek, infratemporal
fossa, or pterygoid or cribriform plates.
The good LC seen in our study was associated with a
high rate of grade ¸2 late toxicity (30 %). However, the
incidence of serious late toxicity was reduced over time
with the implementation of IMRT compared to 2D and
3DCRT, albeit statistically not signiWcant (14 vs. 57 %;
respectively p = 0.2). Furthermore, the incidence of perma-
nent visual impairment was signiWcantly reduced in
patients treated by IMRT compared to 2D and 3DCRT with
an ultimate organ preservation rate of 86 and 14 %, respec-
tively (p = 0.006). The improved therapeutic ratio achieved
by the use of IMRT would allow us to escalate the dose of
radiotherapy locally to further improve LC rates, since local
recurrence is the most signiWcant problem in SNUC.
Table 3 Review of literature on treatment outcomes in SNUC
DDHCC Daniel den Hoed Cancer Center, Rotterdam; UCSF University of California, San Franscico; UV University of Virginia; UMAA University
of Michigan, Ann Arbor; MDACC M D Anderson Cancer Center, Houston; UF University of Florida; UC University of Cincinnati, PMCCC Pet-
erMac Callum Cancer Centre, Melbourne; FU follow-up; AJCC American Joint Committee on Cancer; LC local control; RC regional control;
DMFS distant metastasis-free survival; DFS disease-free survival; CSS cause-speciWc survival; OS overall survival
a Three-year outcomes were reported
DDHCC UCSF [2] UV [3] UMAA [4] MDACC [5] UF [6]a UC [7] PMCCC [8]
No. of patients 21 21 20 19 16 15 14 10
Years of inclusion 1996–2010 1990–2004 1986–2000 1995–2008 1982–2002 1992–2005 1970–1999 1990–2002
Median age (years) 52 47 58 51 48 57 54 49
Median FU time (months) 54 58 80 21 81 30
Median RT dose (Gy) 62.5 57 55 60 64.8 61 54
AJCC T4 (%) 71 81 73 84 69 100 63 90
Node positive (%) 10 10 13 21 0 13 30
Surgery (%) 62 90 55 53 63 66 64 20
Radiotherapy (%) 100 100 95 100 100 93 86 100
Chemotherapy (%) 76 62 80 84 47 43 70
2 year LC (%) 80 60 83 43 50
5 year LC (%) 80 56 79 78
2 year RC (%) 94 50 50
5 year RC (%) 90 90 84 80
2 year DMFS (%) 80
5 year DMFS (%) 90 64 35 75 82
2 year OS (%) 74 47 61 45 64
5 year OS (%) 74 43 20 22 63 67
5 year CSS (%) 74 77123
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Local recurrence and DM remain signiWcant problems in
patients with SNUC. Treatment strategies to improve
outcomes should therefore focus on improving local and
distant disease control. In a recent review of Robbins and
colleagues [13], recommendations for the future direc-
tion of therapeutic investigations are outlined. According
to that review, further progress in the treatment of SNUC
could be achieved through the development of endo-
scopic surgery, high-precision high-dose radiotherapy,
and further intensiWcation of chemotherapeutic sched-
ules. The slightly improved LC rates, the reduction in the
late toxicity and permanent visual impairment, and sub-
sequent improvement in the therapeutic ratio seen by the
implementation of IMRT should allow dose escalation of
radiotherapy to further improve LC, since dose–response
relationship might exist in case of SNUC [11]. To further
reduce the risk of late (especially ocular) toxicity, hyper-
fractionated scheme of radiotherapy, as applied to two-
thirds of patients treated at the University of Florida [6],
could be oVered to patients treated with radiotherapy
without chemotherapy, since acceleration of radiother-
apy is probably not beneWcial in concomitant chemora-
diotherapy schedules [14]. Highly conformal new
radiation techniques as proton therapy might oVer new
perspectives in the radiation treatment of SNUC. Mock
et al. [15] showed that protons could achieve 60 % dose
reduction in organs at risk, compared to IMRT while
keeping similar or better target coverage. In patients
were the respectability of the SUNC is doubtful, an
attempt of down-staging by induction chemotherapy
might be considered to subsequently improve LC, DFS,
and OS. Carful selection of patients who were more
likely to beneWt from an attempt of down-staging before
surgical resection is, therefore, of paramount importance.
The randomized controlled study of Hitt et al. [16]
showed that in patients with unresectable locally
advanced head and neck squamous cell carcinoma,
induction chemotherapy with paclitaxel, cisplatin, and
Xuorouracil resulted in an overall response rate of 80 %.
Because limited evidence exists for taxanes in sinonasal
malignancies, the optimal regimen for induction chemo-
therapy needs, therefore, to be explored in prospective
studies. Other possible advantages of induction chemo-
therapy in these patients are the reduction of DM rate
[17], symptomatic relief in patients in need of immediate
therapy, and a logistical advantage to avoid unnecessary
delay in starting radiotherapy because of the waiting
time.
The limitations of the current study are well recognized
by the authors. Inherent to the rarity of the disease, the
number of patients treated is small and it is extremely
diYcult to conduct randomized or even large prospective
studies to investigate diVerent unclear issues with respect to
the optimal treatment of SNUC. Although the conclusions
drawn are of low level of evidence, the results of the pres-
ent study will, in our opinion, strengthen the small bulk of
evidence available in the literature about diVerent issues of
the management of these patients. The late toxicity was ret-
rospectively scored using chart review only. Accurate
assessment of less severe complications from the medical
records is not really reliable because of the subjective
nature of these end points. Therefore, it is likely that not all
mild late toxicities were captured.
Conclusions
In the current study, combined-modality treatment with
three, or at least two, modalities for patients with SNUC
resulted in good LC, but with high overall rate of late toxic-
ity. However, the incidence of late toxicity and visual
impairment were decreased over time by the introduction of
IMRT. The reduction in late toxicity was also associated
with slight improvement in LC rates, albeit statistically
nonsigniWcant. The improved therapeutic ratio achieved by
IMRT would allow dose escalation of radiotherapy and
subsequently improve LC as the most signiWcant problem
in patients with SNUC. Therefore, highly conformal radio-
therapy techniques as IMRT should be the standard of care
in patients with SNUC.
Although all of the reported series in our review are
small, some important conclusions can be drawn from the
review of the literature. First, gross tumor resection
should be considered in all patients, as better outcome has
been noted with the implementation of aggressive surgery
as part of the treatment modality. In case of doubt about
the feasibility of primary surgical resection, induction
chemotherapy would be oVered to patients with good per-
formance and where an attempt of organ preservation is
reasonable. Second, a treatment schedule comprising
three, or at least two, treatment modalities should be
oVered to all patients. The sequence of these modalities
would be dictated by disease extent, performance state,
and the available treatment resources. Furthermore, ENI
would be advocated in all patients with locally advanced
disease, as the results of the small studies where ENI was
applied are encouraging with respect to regional disease
control.
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